RxDoctor Payments Data

Igor Borisov, MD

Internal Medicine · Denver, CONPI 1235134008

Payments from drug & device makers

$1,149in general payments, 2019–2025

Across 50 payments — averaging $22.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$198
  • Novo Nordisk$173
  • AstraZeneca$127
  • Lilly USA, LLC$100
  • Astellas Pharma US Inc$94
  • Amgen$87
  • plus $369 from 12 others

What the payments were for

  • Food & beverage$1,149100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,149 in reported general payments places this provider in the 85th percentile of 1,430 internal medicine providers in Colorado.

See all internal medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$305,234
Medicare patients
144
Services billed
4,162

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban105$98,516
TrulicityDulaglutide43$44,777
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$44,132
XareltoRivaroxaban38$41,108
OzempicSemaglutide35$36,067
LinzessLinaclotide36$28,814
MounjaroTirzepatide11$20,652
Tresiba Flextouch U-200Insulin Degludec22$16,869
TradjentaLinagliptin12$12,478
CreonLipase/Protease/Amylase17$10,117
Atrovent HfaIpratropium Bromide16$7,428
Dexlansoprazole DrDexlansoprazole45$6,918
JanuviaSitagliptin Phosphate11$6,741
JanumetSitagliptin Phos/Metformin Hcl12$6,737
BelsomraSuvorexant12$5,071

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$26$101,972116 claims
Lilly USA, LLCTrulicity, Mounjaro$100$65,42954 claims
GSKTrelegy Ellipta, Shingrix$198$47,39457 claims
Johnson & JohnsonXarelto$50$41,10838 claims
Novo NordiskOzempic$173$36,06735 claims
MerckJanuvia, Janumet, Belsomra$19$18,54935 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,430 internal medicine providers in Colorado.

Other internal medicine in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →